Drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Freeze branding was rapidly adopted by European livestock operations, as dry ice and liquid nitrogen are easily procured there thanks to denser infrastructure and transport networks. The technique has also been embraced by many breeder associations such as the Arabian Horse Registry as a more humane method of permanently identifying animals. Cryo-branding has been especially welcomed by tanners, whose antipathy towards hot branding is as old as hot branding itself. Freeze branding does not damage the lower corium layer dividing skin from subcutaneous tissue. The far less extensive skin injury caused by freeze branding greatly reduces the persistence of the mark in finished leather. Tanners have often advocated for placing the brand on the cow's jaw rather than the haunches or the saddle, the source of the best quality leather on an animal's hide. Scientific studies have verified freeze branding as effective on the jaws of cattle. Jaw branding has the disadvantage of a cow's tendency to turn its head and return the gaze of a person trying to inspect its brand, hiding it from view. Farrell continued searching for novel means of destroying pigmentation to create permanent marks on animals. In the early 1970s, he pioneered the use of lasers to brand fish while still underwater. He received a patent in 1975 for the method, which involved a bundle of fiber optic light channels held to a fish's side.
=== Environment === PMOS may also be impacted by epigenetics, which regulates how active genes are. High levels of androgens and AMH during pregnancy and early weight gain can hinder the fetal environment. In studies of PMOS in mice, exposure to AMH or the androgen dihydrotestosterone still has an effect three generations later. If that is so in humans, it implies that PMOS can be inherited via epigenetic changes. Blood in the umbilical cord of babies whose mothers have PMOS shows specific epigenetic changes suggestive of PMOS. There is little evidence on the effect of environmental pollutants on PMOS risk. Hormone disruptors are chemicals that disturb the hormonal system by blocking or mimicking natural hormones. Of these, bisphenol A and phthalates (both used in plastics), and possibly octocrylene exposure may raise the risks of PMOS. Obesity is implicated in PMOS development. As fat tissue can produce androgens, obesity leads to increased androgen levels. It also leads to suppression of the SHBG hormone, increased insulin resistance, and abnormally increased insulin levels. Some of the effects go both ways: PMOS might impact appetite, so that weight gain becomes more likely. Weight loss using diet is equally effective in people with and without PMOS.
== Technology license == The Scripps Research Institute has a portfolio of click-chemistry patents. Licensees include Invitrogen, Allozyne, Aileron, Integrated Diagnostics, and the biotech company baseclick, a BASF spin-off created to sell products made using click chemistry. Moreover, baseclick holds a worldwide exclusive license for the research and diagnostic market for the nucleic acid field. Fluorescent azides and alkynes are also produced by companies such as Cyandye.
Sources: en.wikipedia.org
== Clinical significance == The inherited disease, dystrophic epidermolysis bullosa, is caused by recessive or dominant mutations in COL7A1. Recessive dystrophic epidermolysis bullosa, the most severe type of epidermolysis bullosa, has two subtypes, generalized intermediate and generalized severe, which have been linked to different mutations in the COL7A1 gene. Recessive dystrophic epidermolysis bullosa, generalized intermediate, is caused primarily by missense, in-frame, and splice-site mutations on one allele. The generalized severe subtype may be caused by premature termination codons in both alleles. These mutations cause little to no expression of collagen VII, which manifests primarily as generalized blistering in the skin and mucosal membranes. This blistering may also lead to several other complications, such as eye abrasions, esophageal stricture, deformity of the hands and feet, and squamous cell carcinoma, among others. Dominant dystrophic epidermolysis bullosa is most often caused by missense mutations, especially glycine substitutions in the collagenous domain. The symptoms of dominant dystrophic epidermolysis bullosa are less severe than those of the recessive types, with mild blistering and loss of nails. Epidermolysis bullosa acquisita involves an autoimmune reaction to this form of collagen. Beremagene geperpavec (Vyjuvek), is a gene therapy indicated for the treatment of wounds for people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
The speaker of the Riksdag nominates a prime minister (Swedish: statsminister, literally minister of state) after holding talks with leaders of the various party groups in the Riksdag. The nomination is then put to a vote. The nomination is rejected (meaning the speaker must find a new nominee) only if an absolute majority of the members (175 members) vote "no"; otherwise, it is confirmed. This means the Riksdag can consent to a prime minister without casting any "yes" votes. After being elected the prime minister appoints the cabinet ministers and announces them to the Riksdag. The new Government takes office at a special council held at the Royal Palace before the monarch, at which the speaker of the Riksdag formally announces to the monarch that the Riksdag has elected a new prime minister and that the prime minister has chosen his cabinet ministers. The Riksdag can cast a vote of no confidence against any single cabinet minister (Swedish: statsråd), thus forcing a resignation. To succeed, a vote of no confidence must be supported by an absolute majority (175 members) or it has failed. If a vote of no confidence is cast against the prime minister this means the entire government is rejected. A losing government has one week to call for a general election or else the procedure of nominating a new prime minister starts anew.
Other species of ants can form chains to bridge gaps over water, underground, or through spaces in vegetation. Some species also form floating rafts that help them survive floods. These rafts may also have a role in allowing ants to colonise islands. Polyrhachis sokolova, a species of ant found in Australian mangrove swamps, can swim and live in underwater nests. Since they lack gills, they go to trapped pockets of air in the submerged nests to breathe.
Sources: en.wikipedia.org
=== Nutrition === The high levels of muscle growth and repair achieved by bodybuilders require a specialized diet. Generally speaking, bodybuilders require more calories than the average person of the same weight to provide the protein and energy requirements needed to support their training and increase muscle mass. In preparation of a contest, a sub-maintenance level of food energy is combined with cardiovascular exercise to lose body fat. Proteins, carbohydrates and fats are the three major macronutrients that the human body needs to build muscle. The ratios of calories from carbohydrates, proteins, and fats vary depending on the goals of the bodybuilder.
John Cowan – bass, lead and backing vocals (1993–1995, 2010–present) Marc Russo – saxophones (1998–present) Ed Toth – drums, percussion (2005–present) Marc Quiñones – percussion, backing vocals (2018–present)
=== Naming === Paracetamol is the Australian Approved Name and the British Approved Name as well as the international nonproprietary name that is used by the World Health Organization (WHO); acetaminophen is the United States Adopted Name and the Canadian and Japanese Accepted Name. Both paracetamol and acetaminophen are contractions of chemical names for the compound. The word paracetamol is a shortened form of para-acetylaminophenol, and was coined by Frederick Stearns & Co in 1956, while the word acetaminophen is a shortened form of N-acetyl-p-aminophenol (APAP), which was coined and first marketed by McNeil Laboratories in 1955. The initialism APAP is used by dispensing pharmacists in the United States.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.